| Trial ID: | L5538 |
| Source ID: | NCT03115099
|
| Associated Drug: |
Ly3325656
|
| Title: |
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3325656|DRUG: Placebo|DRUG: Liraglutide|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through approximately 12 weeks and 5 weeks after first administration of study drug in Parts A and B, respectively | Secondary: Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3325656, Pharmacokinetics: Area Under the Concentration Curve of LY3325656 From Time Zero to 24 Hours \[AUC(0-24)\], Baseline up to 72 hours after each dose of study drug|Pharmacokinetics: Maximum Concentration (Cmax) of LY3325656, Pharmacokinetics: Maximum Concentration (Cmax) of LY3325656, Baseline up to 72 hours after each dose of study drug
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2017-05-31
|
| Completion Date: |
2018-04-05
|
| Results First Posted: |
|
| Last Update Posted: |
2018-08-23
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Singapore, 117597, Singapore|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
|
| URL: |
https://clinicaltrials.gov/show/NCT03115099
|
